Fig. 9

CircNRIP1 plays a tumour promotor role during GC growth in vivo. a. The circNRIP1 overexpression plasmid and cholesterol-conjugated circNRIP1 siRNA were continuously injected intratumorally into PDX mice. b. The donor patients were clinically characterized. c. The engrafted tumours were histopathologically analysed, scale bar = 100 μm. d. We found that circNRIP knockdown in vivo significantly blocked tumour growth in terms of tumour weight and volume relative to the negative control group, whereas overexpression of circNRIP1 promoted the growth of xenografted tumours. e. qRT-PCR was performed in PDX tumours, and we found increased and persistent levels of circNRIP1 in the circNRIP1 overexpression plasmid-treated groups relative to the NC group and lower levels of circNRIP1 in the long-term circNRIP1 siRNA-treated groups. f. The expression levels of p-AKT1, p-mTOR, PFK, LC3 and EMT markers were observed in PDX tumour tissues by western blotting. g. The expression levels of AKT1 and mTOR were again observed in PDX tumours by IHC, scale bar = 100 μm. All data are presented as the mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001